WCN25-744 FELZARTAMAB SELECTIVELY AND POTENTLY TARGETS CD38+ ANTIBODY SECRETING CELLS FROM PATIENTS WITH IMMUNE-MEDIATED KIDNEY DISEASES

Saved in:
Bibliographic Details
Main Authors: Kristina Ilieva, Karin Landgraf, Rainer Boxhammer, Stefan Steidl, Donna Flesher
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Kidney International Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024924023520
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850223727086665728
author Kristina Ilieva
Karin Landgraf
Rainer Boxhammer
Stefan Steidl
Donna Flesher
author_facet Kristina Ilieva
Karin Landgraf
Rainer Boxhammer
Stefan Steidl
Donna Flesher
author_sort Kristina Ilieva
collection DOAJ
format Article
id doaj-art-0d877b8337b44edb9d6fc5cf7e614c1c
institution OA Journals
issn 2468-0249
language English
publishDate 2025-02-01
publisher Elsevier
record_format Article
series Kidney International Reports
spelling doaj-art-0d877b8337b44edb9d6fc5cf7e614c1c2025-08-20T02:05:50ZengElsevierKidney International Reports2468-02492025-02-01102S16010.1016/j.ekir.2024.11.330WCN25-744 FELZARTAMAB SELECTIVELY AND POTENTLY TARGETS CD38+ ANTIBODY SECRETING CELLS FROM PATIENTS WITH IMMUNE-MEDIATED KIDNEY DISEASESKristina Ilieva0Karin Landgraf1Rainer Boxhammer2Stefan Steidl3Donna Flesher4Translational Research, MorphoSys AG, Planegg, GermanyTranslational Research, MorphoSys AG, Planegg, GermanyClinical Biomarker & CDx, MorphoSys AG, Planegg, GermanyTranslational Research, MorphoSys AG, Planegg, GermanyBiomarker and Bioanalytical Sciences, Human Immunology Biosciences, Inc., a Biogen company, South San Francisco, United Stateshttp://www.sciencedirect.com/science/article/pii/S2468024924023520
spellingShingle Kristina Ilieva
Karin Landgraf
Rainer Boxhammer
Stefan Steidl
Donna Flesher
WCN25-744 FELZARTAMAB SELECTIVELY AND POTENTLY TARGETS CD38+ ANTIBODY SECRETING CELLS FROM PATIENTS WITH IMMUNE-MEDIATED KIDNEY DISEASES
Kidney International Reports
title WCN25-744 FELZARTAMAB SELECTIVELY AND POTENTLY TARGETS CD38+ ANTIBODY SECRETING CELLS FROM PATIENTS WITH IMMUNE-MEDIATED KIDNEY DISEASES
title_full WCN25-744 FELZARTAMAB SELECTIVELY AND POTENTLY TARGETS CD38+ ANTIBODY SECRETING CELLS FROM PATIENTS WITH IMMUNE-MEDIATED KIDNEY DISEASES
title_fullStr WCN25-744 FELZARTAMAB SELECTIVELY AND POTENTLY TARGETS CD38+ ANTIBODY SECRETING CELLS FROM PATIENTS WITH IMMUNE-MEDIATED KIDNEY DISEASES
title_full_unstemmed WCN25-744 FELZARTAMAB SELECTIVELY AND POTENTLY TARGETS CD38+ ANTIBODY SECRETING CELLS FROM PATIENTS WITH IMMUNE-MEDIATED KIDNEY DISEASES
title_short WCN25-744 FELZARTAMAB SELECTIVELY AND POTENTLY TARGETS CD38+ ANTIBODY SECRETING CELLS FROM PATIENTS WITH IMMUNE-MEDIATED KIDNEY DISEASES
title_sort wcn25 744 felzartamab selectively and potently targets cd38 antibody secreting cells from patients with immune mediated kidney diseases
url http://www.sciencedirect.com/science/article/pii/S2468024924023520
work_keys_str_mv AT kristinailieva wcn25744felzartamabselectivelyandpotentlytargetscd38antibodysecretingcellsfrompatientswithimmunemediatedkidneydiseases
AT karinlandgraf wcn25744felzartamabselectivelyandpotentlytargetscd38antibodysecretingcellsfrompatientswithimmunemediatedkidneydiseases
AT rainerboxhammer wcn25744felzartamabselectivelyandpotentlytargetscd38antibodysecretingcellsfrompatientswithimmunemediatedkidneydiseases
AT stefansteidl wcn25744felzartamabselectivelyandpotentlytargetscd38antibodysecretingcellsfrompatientswithimmunemediatedkidneydiseases
AT donnaflesher wcn25744felzartamabselectivelyandpotentlytargetscd38antibodysecretingcellsfrompatientswithimmunemediatedkidneydiseases